44
Participants
Start Date
October 24, 2017
Primary Completion Date
November 10, 2018
Study Completion Date
November 10, 2018
Other
Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
Research Site, White Plains
Research Site, Annapolis
Research Site, Hendersonville
Research Site, Asheville
Research Site, Fort Lauderdale
Research Site, Deerfield Beach
Research Site, Kettering
Research Site, Southfield
Research Site, Harvey
Research Site, Chicago
Research Site, Boise
Research Site, Farmington
Research Site, Los Angeles
Research Site, Anaheim
Research Site, St. Helena
Research Site, Santa Rosa
Research Site, Honolulu
Research Site, Seattle
Research Site, Seattle
Research Site, Brick
Research Site, Edmonton
Research Site, Newmarket
Research Site, Montreal
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
AstraZeneca
INDUSTRY